Logs: Bang Zheng
The following is a list of all job requests run via OpenSAFELY by Bang Zheng.
| Status | Organisation | Project | Workspace | Request ID | Backend | Jobs | Started | View request |
|---|---|---|---|---|---|---|---|---|
| Succeeded | The London School of Hygiene & Tropical Medicine | Effectiveness safety sotrovimab molnupiravir | sotrovimab_molnupiravir | 17508 | TPP | 1/1 | 2 years, 10 months ago 07 May 2023 18:25:27 UTC | View, Job request 17508 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 17425 | TPP | 1/1 | 2 years, 9 months ago 13 May 2023 13:05:13 UTC | View, Job request 17425 |
| Succeeded | The London School of Hygiene & Tropical Medicine | Effectiveness safety sotrovimab molnupiravir | sotrovimab_molnupiravir | 17004 | TPP | 1/1 | 2 years, 11 months ago 08 April 2023 17:33:18 UTC | View, Job request 17004 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 17003 | TPP | 1/1 | 2 years, 11 months ago 08 April 2023 17:20:33 UTC | View, Job request 17003 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16669 | TPP | 2/2 | 2 years, 11 months ago 23 March 2023 22:39:57 UTC | View, Job request 16669 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16667 | TPP | 1/1 | 2 years, 11 months ago 23 March 2023 17:00:30 UTC | View, Job request 16667 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16660 | TPP | 1/1 | 2 years, 11 months ago 23 March 2023 16:32:05 UTC | View, Job request 16660 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16657 | TPP | 0/1 | 2 years, 11 months ago 23 March 2023 13:43:15 UTC | View, Job request 16657 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16640 | TPP | 0/1 | 2 years, 11 months ago 23 March 2023 11:24:48 UTC | View, Job request 16640 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16637 | TPP | 0/1 | 2 years, 11 months ago 23 March 2023 09:47:44 UTC | View, Job request 16637 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16630 | TPP | 0/1 | 2 years, 11 months ago 23 March 2023 07:14:37 UTC | View, Job request 16630 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16629 | TPP | 0/1 | - | View, Job request 16629 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16628 | TPP | 0/1 | 2 years, 11 months ago 22 March 2023 23:27:59 UTC | View, Job request 16628 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16627 | TPP | 0/1 | 2 years, 11 months ago 22 March 2023 22:35:06 UTC | View, Job request 16627 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16624 | TPP | 0/1 | 2 years, 11 months ago 22 March 2023 20:56:58 UTC | View, Job request 16624 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16586 | TPP | 1/1 | 2 years, 11 months ago 21 March 2023 22:45:36 UTC | View, Job request 16586 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16585 | TPP | 0/1 | 2 years, 11 months ago 21 March 2023 21:35:52 UTC | View, Job request 16585 |
| Failed | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16573 | TPP | 0/1 | 2 years, 11 months ago 21 March 2023 20:29:48 UTC | View, Job request 16573 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16384 | TPP | 5/5 | 2 years, 11 months ago 15 March 2023 22:10:43 UTC | View, Job request 16384 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16372 | TPP | 1/1 | 2 years, 11 months ago 15 March 2023 18:00:20 UTC | View, Job request 16372 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16370 | TPP | 1/1 | 2 years, 11 months ago 15 March 2023 17:20:22 UTC | View, Job request 16370 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16289 | TPP | 5/5 | 2 years, 11 months ago 14 March 2023 12:38:57 UTC | View, Job request 16289 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16277 | TPP | 1/1 | 2 years, 11 months ago 14 March 2023 08:54:11 UTC | View, Job request 16277 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16276 | TPP | 1/1 | 2 years, 11 months ago 13 March 2023 23:39:06 UTC | View, Job request 16276 |
| Succeeded | Bennett Institute | Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 | paxlovid_sotrovimab | 16275 | TPP | 1/1 | 2 years, 11 months ago 13 March 2023 22:47:42 UTC | View, Job request 16275 |